Clinical Study

Abbvie M19-700- A Phase 1B Study Of Venetoclax In Combination With Pembrolizumab In Subjects With Previously Untreated Nsclc Whose Tumors Have High Pd-L1 Expression

Posted Date: Jul 8, 2020

  • Investigator: John Morris
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The primary goal of this study is to determine the recommended dose of venetoclax in combination with pembrolizumab based on safety and anti-tumor activity (including tumor size kinetics).

Criteria:

To Be Eligible: Must Have Histologically Documented Advanced Or Metastatic Nsclc, Ecog 0 Or 1, At Least One Measurable Lesion, No Prior Treatment With Any Anti-Pd-1, Or Pd-L1 Or Pd-L2 Agent, No Known Cns Metastases, No Other Malignancy Within 3 Years, No Current Or Past Infection Or Comorbidity That May Impact Study Treatment/Safety,

Keywords:

Lung Cancer, Nsclc

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.